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Abstract: Background: In 2016 we observed a marked increase in functional delayed graft function
(fDGF) in our living donor kidney transplantation (LDKT) recipients from 8.5% in 2014 and 8.8% in
2015 to 23.0% in 2016. This increase coincided with the introduction of a goal-directed fluid therapy
(GDFT) protocol in our kidney transplant recipients. Hereupon, we changed our intraoperative fluid
regimen to a fixed amount of 50 mL/kg body weight (BW) and questioned whether the intraoperative
fluid regimen was related to this increase in fDGF. Methods: a retrospective cohort analysis of all
donors and recipients in our LDKT program between January 2014–February 2017 (n = 275 pairs).
Results: Univariate analysis detected various risk factors for fDGF. Dialysis dependent recipients
were more likely to develop fDGF compared to pre-emptively transplanted patients (p < 0.001).
Recipients developing fDGF received less intraoperative fluid (36 (25.9–50.0) mL/kg BW vs. 47
(37.3–55.6) mL/kg BW (p = 0.007)). The GDFT protocol resulted in a reduction of intraoperative
fluid administration on average by 850 mL in total volume and 21% in mL/kg BW compared to
our old protocol (p < 0.001). In the unadjusted analysis, a higher intraoperative fluid volume in
mL/kg BW was associated with a lower risk for the developing fDGF (OR 0.967, CI (0.941–0.993)).
After adjustment for the confounders, prior dialysis and the use of intraoperative noradrenaline,
the relationship of fDGF with fluid volume was still apparent (OR 0.970, CI (0.943–0.998)). Conclusion:
Implementation of a GDFT protocol led to reduced intraoperative fluid administration in the LDKT
recipients. This intraoperative fluid restriction was associated with the development of fDGF.
Keywords: fluid management; kidney transplantation; delayed graft function; goal-directed fluid therapy
1. Introduction
During the procedure of organ donation and transplantation a number of potentially harmful
processes will inevitably occur, affecting the viability of the kidney graft. Both donor and recipient are
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subjected to anesthesia and surgery, which will produce a sequence of systemic and local changes,
including a significant proinflammatory and procoagulatory response [1]. The donor organ is
by definition, exposed to a number of phases of injury from the moment the donor suffers from
cerebral injury (in case of brain death) until the kidney is reconnected to the circulation in the
recipient. These phases include a profound systemic and local proinflammatory and procoagulatory
response during donor management and retrieval, associated with hypoxia and ischemia of the kidney.
In addition, prolonged warm ischemia in the deceased circulatory death (DCD) donor will affect the
viability of the donor kidney. These combined effects on the graft-to-be result in a cascade of renal
damage that will reveal itself at the time of transplantation, when the donor kidney is reperfused in
the recipient and has been named an ischemia-reperfusion injury (IRI) [2]. Typically, IRI will clinically
manifest as immediate nonfunction of the transplant with the need for dialysis treatment until the
graft recovers from the insult and starts eventually to function. This ‘secondary’ recovery is called
delayed graft function.
DGF, a form of acute kidney injury post-transplantation, is an uncommon complication after living
donor kidney transplantation (LDKT), most likely due to very short ischemia times and healthy living
donors. Incidences reported vary between 1%–8% [3,4]. In transplantation with kidneys from deceased
brain death (DBD) donors, however, the incidence of DGF increases to 15%–25% and may rise up to
72% in transplantation with kidneys from deceased DCD donors [5,6]. DGF is a risk factor for acute
rejection (AR) and the combination of DGF and AR reduces graft and patient survival [7–9]. Also in the
absence of AR, DGF has been shown to be an independent risk factor for long term graft loss. Reported
risk factors for DGF are: deceased donor, longer ischemia times, donor and recipient older age, female
donor, male recipient, history of dialysis, higher body mass index (BMI), hypertension in the donor,
diabetes in the recipient, retransplantation, higher panel-reactive antibody levels, and higher human
leukocyte antigens (HLA) mismatch [3,5,7,10]. This variety of risk factors underscores the complex
pathological mechanisms underlying DGF.
Regarding the intraoperative period, several studies suggest that an adequate/supranormal
fluid state is associated with a reduced risk of DGF [5,7,11–14]. These studies, however, are mainly
retrospective and often comprise a variety of donor types with variable incidences of DGF hampering
an adequate analysis. Central venous pressure (CVP)-guided fluid therapy has been suggested
until recently [11,12], but CVP does not correlate well with intravascular fluid state and its use to
guide fluid therapy is currently discouraged [15]. Blood pressure and heart rate are also affected by
several variables, unrelated to the circulatory state of the patient, like pain, temperature, anesthetics,
and analgesics, making them less suitable as an indicator of the intravascular volume [16,17].
Recently, goal directed fluid therapy (GDFT) has been shown to improve patient outcomes after
major (abdominal) surgery [18–20]. During 2015, our department implemented a GDFT approach in
kidney transplant recipients to replace our standard intraoperative fluid regimen of four to five liters
(L) of balanced crystalloids. In the first half year of 2016 a marked increase in DGF and functional
(f)DGF in our LDKT population was noticed. During 2014 and 2015, respectively, 8.5% and 8.8% of
the patients experienced fDGF. From January to June 2016 the incidence of functional delayed graft
function (fDGF) rose to 23.0%, which was a significant increase compared to 2014 and 2015 (p = 0.039
and p = 0.021, respectively). Since the incidence of fDGF in this population has been stable over the
past two decades and no protocol changes were implemented with the exception of the GDFT protocol,
we questioned whether this increase in fDGF was due to the altered fluid regimen. To our surprise,
a retrospective analysis revealed that the implementation of GDFT protocol had resulted in a reduced
intraoperative fluid administration which seemed associated with the increase in fDGF. Based on these
results, we promptly changed the intraoperative fluid protocol in September 2016 to a fixed amount of
50 mL/kg BW with a lower limit of 2500 mL and upper limit of 6000 mL (50 kg–120 kg), unless patients
comorbidity determined otherwise. After six months the incidence of fDGF was back to baseline
at 8.2%.
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Since we were interested in whether the amount of fluid administered intraoperatively was indeed
an independent factor predicting fDGF in this LDKT population, we performed a retrospective cohort
analysis of all donors and recipients in our living donor program between January 2014–February 2017.
2. Materials and Methods
2.1. Study Design and Population
This retrospective cohort analysis comprised all consecutive donor and recipient pairs of the
LDKT program of the University Medical Centre of Groningen (UMCG) between January 2014 and
February 2017. The Institutional Review Board approved the study (METc 201600968), which was
conducted in adherence to the Declaration of Helsinki. Due to the observational and retrospective
character of the analysis, the requirement for informed consent was waived.
2.2. Definition of DGF
Twenty-two definitions of DGF were identified in literature based on dialysis, serum creatinine
levels, urine output or a combination of these 3 [21], Most commonly used was dialysis requirement
the first week after transplantation (also used in this analysis for DGF). This dialysis-based definition,
however, is criticized for its subjectivity since there are center- or physician-specific thresholds for
the use of dialysis after transplantation [22]. Furthermore, since approximately half of our LDKT
population was transplanted preemptively, this dialysis-based definition was unsuitable for this
analysis. Another definition, referred to as functional (f)DGF, is failure of serum creatinine level to
decrease spontaneously by at least 10% daily on 3 consecutive days during the first postoperative
week, discounting creatinine decreases due to dialysis. Moore and colleagues showed that fDGF is
independently associated with reduced death-censored graft survival in contrast to DGF based on the
dialysis definition and suggested a superiority of this definition over the dialysis-based definition [23].
To prevent misclassification in patients with excellent early graft function, failure of creatinine to
decrease on postoperative day three was not classified as fDGF if optimal graft function had already
been achieved by day 2. In this analysis, we compared patients undergoing LDKT with fDGF and
without fDGF (nofDGF).
2.3. Intra- and Postoperative Management and Surgical Procedure
Anesthetic management was according to local protocol. Propofol was used for induction of
anesthesia and either propofol or sevoflurane were used for maintenance of anesthesia. Sufentanil or
remifentanil were used to control nociception and rocuronium or cis-atracurium for muscle relaxation.
Until the implementation of the GDFT protocol, donors and recipients were given 4–5 L of balanced
crystalloids throughout the procedure unless their comorbidity determined otherwise. During 2015,
a GDFT protocol was gradually implemented in the recipients (not in the donors). For a detailed
description of this protocol, see below. From September 2016 fluid protocol in recipients was changed
to a fixed amount of 50 mL/kg BW intraoperatively. Timeline of fluid management in recipients is given
in Figure 1. Fluid management in donors was not actively changed during our observation period.
Regarding the type of fluid, predominantly Ringers’ lactate (RL) was used. If hyponatremia occurred
RL was replaced by 0.9% saline. Colloids were not given and administration of blood products was
according to our local transfusion protocol with thresholds based upon patients comorbidity. Regarding
hemodynamics, the goal was to keep the blood pressure within 80% range of the baseline blood pressure
of the patient. As baseline, we used blood pressure measured at the preoperative visit. If hypotension
occurred, the first step was to adjust depth of anesthesia or analgesia. If that was insufficient or not
possible, patients received one or more doses of ephedrine or phenylephrine or a continuous infusion
of noradrenaline was started. Kidney donation was performed using a hand-assisted laparoscopic
approach. Thereafter the kidney was flushed and perfused with cold University of Wisconsin solution
(ViaSpan®, BMS, Bruxelles, Belgium or CoStorSol®, Bridge to Life, Elkhorn, WI, USA) and stored on
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ice. Transplantation was performed according to local, standardized protocol. Postoperative fluid
management comprised 1 L NaCl 0.45%-Glucose 2.5% per 24 h, complemented with the volume of
diuresis in the former hour.
Figure 1. Timeline of various intraoperative fluid protocols in recipients. L: liters; RL: Ringers’ lactate;
GDFT: goal directed fluid therapy, BW: body weight.
2.4. Goal-Directed Fluid Therapy Protocol.
GDFT was performed with the use of the FloTrac®in combination with the EV1000®monitor
(Edwards Lifesciences Corporation, Irvine, CA, USA). The system was used according to manufacturer’s
instructions. A standard institutional GDFT protocol was used with adjustment of the goal. Instead
of a stroke volume variation (SVV) < 12%, commonly used in abdominal surgery, we aimed for
a SVV < 10% throughout the procedure. When the SVV was >10% additional fluid was given until SVV
was <10%. If SVV < 10%, fluid administration was left to the discretion of the attending anesthesiologist,
however, when cardiac index (CI) was below age-adjusted normal values, a noradrenaline infusion was
started. If measurement of the SVV was not possible (e.g., due to cardiac arrhythmias) a protocol based
on stroke volume (SV) was used. In this case, if a fluid bolus of 250 mL resulted in an increase of the SV
of 10%, additional fluid was given, if not, the trend of the SV was monitored and fluid administration
was left to the discretion of the attending anesthesiologist. When SV decreased >10%, additional fluid
was given. The FloTrac®was used with the EV1000 monitor, which does not communicate with our
digital PDMS. Therefore SV, SVV, and CI values could not be retrieved for this analysis.
2.5. Patient Data
Demographic and postoperative data were obtained from digital patient medical records. The following
variables were taken into account: age, gender, BMI, smoking, hypertension, use of antihypertensive drugs,
measured glomerular filtration rate (mGFR) with use of iodine 125-iothalamate in the donor, blood pressure
(measured the day of hospital admission), difference in blood pressure between donor and recipient
measured by systolic/diastolic/mean of the recipient minus systolic/diastolic/mean of the donor, underlying
kidney disease, number of HLA mismatches, history of dialysis, related or unrelated donor transplantation.
For all recipients, the age-adjusted Charlson comorbidity index (CCI) [24] and length of hospital stay was
calculated. Intraoperative data were retrieved from our digital patient data monitoring system (PDMS,
CS-EZIS, Chipsoft B.V., Amsterdam, the Netherlands) and consisted of duration of surgery, intraoperative
volume and type of fluid, cumulative hypotensive periods defined as a systolic blood pressure < 80 mmHg
and MAP < 60 mmHg, intraoperative use of vasoactive substances, ischemia times, left/right kidney,
side of implantation, number of arteries, sacrifice of an accessory artery, and urinary output the first 2
h postoperatively. Regarding the use of vasoactive substances, patients were scored on receiving one or
more boluses of ephedrine and/or phenylephrine and whether or not noradrenaline was administered as
a continuous infusion. Additionally, the maximum noradrenaline infusion rate during the procedure was
noted. This was grouped into 3 categories: low infusion rate (0.02–0.10 mg/h), intermediate (0.10–0.20 mg/h),
and high (>0.20 mg/h) infusion rate.
2.6. Statistics
For the statistical analysis SPSS version 23 (IBM Corp, Armonk, NY, USA) and GraphPad Prism
version 7.02 (GraphPad Software Inc, La Jolla, CA, USA) were used. We performed univariate analyses
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to identify factors associated with fDGF. Categorical data were analyzed by chi-square or Fisher’s
exact tests. Continuous data were analyzed with an unpaired t-test in the case of normally distributed
values. If variables were not normally distributed Mann–Whitney test was applied. Multivariate
analysis was performed by means of binary logistic regression. We adjusted the amount of fluid
administered intraoperatively in recipients for potentially relevant confounders with high significance
in the univariate analysis. Additionally, we were interested in the impact of implementation of our
GDFT protocol on the incidence of fDGF and on the amount of fluid administered intraoperatively.
We therefore analyzed these data between the different time periods 1–3 (described above) with the
use of Fisher’s exact test and Kruskal–Wallis test. Post-hoc analysis with Mann–Whitney was used.
Values are given as number (%), mean ± standard deviation (SD) or median with interquartile range
(IQR). All reported p-values are two-sided. A p-value of 0.05 or less was considered significant.
3. Results
3.1. Univariate Analysis
3.1.1. Patient Characteristics
Between January 2014 and February 2017, 275 living donor kidney transplant procedures were
performed in our center. Of the 275 recipients, 31 patients experienced fDGF and 244 recipients did
not (nofDGF). Donor and recipients characteristics of fDGF and nofDGF kidneys are listed in Table 1.
There were no statistically significant differences in baseline characteristics and kidney function (mGFR)
in donors of kidneys with our without fDGF. Recipients developing fDGF were more likely to be
dialysis-dependent at the time of transplantation (25 (81%) vs. 105 (43%), p < 0.001). The composition
of the group of dialysis dependent patients did not differ between nofDGF and fDGF recipients. In the
nofDGF group 76 (72%) patients were on hemodialysis at the time of transplantation and 29 (28%)
on peritoneal dialysis. In the fDGF group, this was the case for 19 (76%) and six (24%), respectively.
All patients on hemodialysis were dialyzed the day before transplantation to 1 kg above dry weight.
Table 1. Donor and recipient demographics. Data given as number (%), mean (SD), or median (IQR).
nofDGF fDGF p
Donor N = 244 N = 31
Age year 54 (11.6) 51 (12.4) 0.104
Gender male 117 (48%) 20 (65%) 0.089
BMI 26.1 (3.0) 25.1 (2.7) 0.075
Smoking 67 (27%) 13 (42%) 0.140
Blood pressure
S-RR mmHg 136 (15.3) 136 (11.8) 0.848
D-RR mmHg 79 (73–84) 81 (73–86) 0.548
MAP mmHg 98 (9.4) 98 (6.7) 0.897
Hypertension 38 (16%) 2 (6%) 0.277
Anti-hypertensive drugs
Diuretics 11 1 >0.999
B-blocker 13 1 >0.999
Ca antagonist 10 0 0.610
ACE-I 4 0 >0.999
AT-II-ant. 16 1 0.703
mGFR
Non-stimulated mL/min 109 (97–23) 107 (95–128) 0.846
Stimulated mL/min 116 (103–133) 118 (100–140) 0.764
∆GFR 7 (2–12) 7 (−1–12) 0.810
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Table 1. Cont.
nofDGF fDGF p
Recipient N = 244 N = 31
Age year 54 (41−61) 55 (43−62) 0.991
Gender male 138 (57%) 21 (68%) 0.254
BMI 25.6 (22.6–28.4) 25.8 (24.0–29.8) 0.267
Smoking 45 (18%) 7 (23%) 0.626
Blood pressure
S-RR mmHg 143 (20.4) 138 (23.7) 0.196
D-RR mmHg 79 (73–84) 81 (73–86) 0.548
MAP mmHg 97 (9.4) 98 (6.6) 0.897
∆ blood pressure with donor
∆ S-RR mmHg 7.1 (22.8) 2.5 (29.1) 0.308
∆ D-RR mmHg 3.1 (13.9) 1.0 (15.0) 0.336
∆ MAP mmHg 4 (−6–14) 8 (−10–12) 0.756
Hypertension 175 (72%) 21 (68%) 0.675
Antihypertensive drugs
Diuretics 84 (34%) 8 (25%) 0.421
B-blocker 124 (51%) 10 (32%) 0.058
Ca antagonist 131 (54%) 15 (48%) 0.703
ACE-I. 46 (19%) 5 (16%) 0.811
AT-II-ant 55 (23%) 7 (23%) >0.999
CCI 3 (2–4) 3 (2–6) 0.157
Underlying kidney disease
DM 15 (6%) 5 (16%) 0.358
PKD 57 (23%) 5 (16%) 0.495
Systemic autoimmune
diseases 25 (10%) 3 (10%) >0.999
Glomerulonephritis 47 (19%) 4 (13%) 0.4713
Other 100 (41%) 14 (45%) 0.701
HLA mm < 3 55 (23%) 8 (25%) 0.655
Dialysis dependent 105 (43%) 25 (81%) <0.001 *
LURD 164 (67%) 19 (61%) 0.547
fDGF: functional delayed graft function; BMI: body mass index; S-RR: systolic blood pressure; D-RR: diastolic blood
pressure; MAP: mean arterial pressure; ACE-I: angiotensin-converting enzyme inhibitor; AT-II-ant: angiotensin
II receptor antagonist; CCI: Charlson comorbidity index; mGFR: measured glomerular filtration rate measured
with use of iodine 125-iothalamate; DM: diabetes mellitus; PKD: polycystic kidney disease; HLA: human leucocyte
antigen; LURD: living unrelated donation; *: statistically significant.
3.1.2. Intra- and Postoperative Data
Intraoperative data of donors of fDGF and nofDGF kidneys showed no differences with exception
of the total amount of fluid, in which donors of fDGF kidneys received less fluid intraoperatively,
which was the case for total volume (3545 mL (778.2) vs. 3845 mL (799.1), p = 0.050) and mL/kg BW
(45 mL/kg BW (10.3) vs. 49 mL/kg BW (11.4), p = 0.053).
Recipients who developed fDGF received significantly less intraoperative fluid, which was the
case for the total amount of fluid (3000 mL (2250–3680) vs. 3500 mL (2900–4075), p = 0.023) and mL
kg-1BW (36 mL/kg BW (25.9–50.0) vs. 47 mL/kg BW (37.3–55.6), p = 0.007). Predominantly RL was
given, but in case of hyponatremia RL was partially replaced by saline. This was the case in 48 (20%)
of the recipients without fDGF and in 8 (26%) of the patients with fDGF (p = 0.477). Median volume
replaced by saline was 1000 mL (500–2000) in the nofDGF group and 800 mL (500–1075) in the fDGF
group (p = 0.865). Blood loss was comparable between groups and transfusion of red blood cells was
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applied in 10 (4.1%) of the patients in the noFDGF group and two (6.4%) of the fDGF group. Patients
showed no difference in hypotensive periods, but recipients experiencing fDGF were treated more
frequently with noradrenaline continuous infusion (p = 0.034), which was only the case for low dose
infusion with a maximum of 0.1 mg/h. For noradrenaline administered at higher dosage (>0.1 mg/h),
there was no difference between the two groups. fDGF was associated with a lower urine output
during the first two hours after transplantation (p = 0.005 for the first hour and p = 0.002 for the second
hour). Ten patients in the fDGF group were dialyzed after transplantation versus zero patients in
the nofDGF group (p < 0.001). Eight of these kidneys gained function after a mean of 10.3 (3.1) days.
Two kidneys suffered primary nonfunction due to a combination of ATN and mild antibody-mediated
rejection (patient 114, transplanted June 2015) and non-HLA-mediated hyperacute rejection (patient
273, transplanted November 2016). Recipients experiencing fDGF showed a longer hospital stay
(14 (10–20) vs. 9 (7–13) days p < 0.001) (Table 2).
Table 2. Intra- and postoperative donor and recipient data. Data given as number (%), mean (SD),
or median (IQR).
nofDGF fDGF p
Donor n = 244 n = 31
Duration min 227 (38.2) 216 (36.8) 0.134
Fluid
Total mL 3845 (799.1) 3545 (778.2) 0.050*
mL/kg BW 49 (11.4) 45 (10.3) 0.053
Intraoperative blood pressure
S-RR ≤ 80 mmHG 137 (56%) 21 (68%) 0.251
Cumulative duration (min) 10 (5–15) 10 (5–15) 0.772
Vasoactive substances
Ephedrine 178 (73%) 25 (71%) 0.515
Phenylephrine 22 (9%) 4 (13%) 0.512
Noradrenaline 61 (25%) 11 (35%) 0.277
Recipient n = 244 n = 31
Duration min 212 (189–239) 224 (190–260) 0.390
Fluid
Total mL 3500(2900–4075)
3000
(2250–3680) 0.023*
mL/kg BW 47 (37.3–55.6) 36 (25.9–50.0) 0.007*
Intraoperative blood pressure
S-RR < 80 mmHg 49 (20%) 6 (19%) >0.999
Cumulative duration min 5 (5–10) 7.5 (4.5–11.2) 0.679
MAP < 60 mmHg 93 (38%) 11 (35%) 0.846
Cumulative duration min 10 (5–10) 5 (5–20) 0.759
Vasoactive substances
Ephedrine 93 (38%) 16 (52%) 0.174
Phenylephrine 26 (11%) 3 (10%) >0999
Noradrenaline 129 (53%) 23 (74%) 0.034*
0.02–0.10 mg h−1 37 (15%) 10 (32%) 0.024*
0.10–0.20 mg h−1 42 (17%) 7 (23%) 0.459
>0.20 mg h−1 49 (20%) 6 (19%) >0.999
Ischemia times (min)
WIT 3 (3–4) 3 (3–4) 0.724
CIT 154 (140–173) 158 (141–178) 0.646
WIT2 39 (33–45) 38 (33–45) 0.982
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Table 2. Cont.
nofDGF fDGF p
Kidney left 177 (73%) 19 (61%) 0.209
Right fossa 203 (83%) 26 (84%) >0.999
>1 artery 49 (20%) 8 (26%) 0.482
Artery sacrificed 11 (5%) 4 (13%) 0.074
Blood loss (mL) 250 (150–400) 250 (162.5–500) 0.499
Urineproduction n = 230 n = 30
1st h (mL) 405 (250–675) 255 (75–512) 0.005*
2nd h (mL) 350 (250–550) 183 (64–462) 0.002*
n = 244 n = 31
Dialysis after transplantation 0 (0%) 10 (32%) <0.001*
Length of hospital stay days 9 (7–13) 14 (10–20) <0.001*
Min: minutes; BW: bodyweight; S-RR: systolic blood pressure; MAP: mean arterial pressure; WIT: warm ischemia
time; CIT: cold ischemia time: WIT2: warm ischemia time 2; *: statistically significant
3.2. Multivariate Logistic Regression Analysis
In the unadjusted analysis, a higher intraoperative administered fluid volume was associated
with 3% lower odds for the development of fDGF per mL/kg BW (OR 0.967, CI (0.941–0.993), model 1).
We adjusted for potentially relevant confounders with high significance in the univariate analysis,
i.e., a history of dialysis and the use of intraoperative noradrenaline, after which the relationship was
still apparent (OR 0.970, CI (0.943–0.998), model 2). Since the intraoperative amount of fluid in the
donors approached significance in the univariate analysis with lower volumes given in the fDGF group,
we also adjusted for amount of fluid in the donor, after which the relationship was still apparent (OR
0.969, CI (0.941–0.997), model 3) (Table 3).
Table 3. Multivariate logistic regression on risk factors of functional delayed graft function (fDGF).
Model Odds ratio(95% CI) p
1. Unadjusted analysis, model 1
• Amount of fluid administered intraoperatively,
recipient, mL/kg BW
0.967
(0.941–0.993) 0.015
2. Adjusted analysis, model 2
• Amount of fluid administered intraoperatively,
recipient, mL/kg BW
0.970
(0.943–0.998) 0.036
• No dialysis dependence at time
of transplantation
0.186
(0.073–0.475) <0.001
• Use of noradrenaline continuous infusion
yes/no
2.018
(0.834–4.878) 0.119
3. Adjusted analysis, model 3
• Amount of fluid administered intraoperatively,
recipient, mL/kg BW
0.969
(0.941–0.997) 0.029
• No dialysis dependence at time
of transplantation
0.181
(0.071–0.464) <0.001
• Amount of fluid administered intraoperatively,
donor, mL/kg BW
0.978
(0.942–1.014) 0.231
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3.3. Influence of the GDFT Protocol on the Intraoperative Fluid Volume.
Additionally, we were interested in the impact of implementation of our GDFT protocol on the
incidence of fDGF and on the amount of fluid administered intraoperatively. The GDFT protocol was
gradually implemented during 2015 and in 2016 (up to September) all recipients were treated following
this protocol (Figure 1). Data of the EV1000 monitor were not recorded in our PDMS, therefore we
were unable to see which patients in 2015 were treated according the GDFT protocol and disregarded
this period (March 2015–December 2015) in this specific analysis. We compared patients transplanted
between January 2014–February 2015 (period 1, n = 84, old protocol) to patients transplanted between
January 2016–June 2016 (period 2, n = 52, GDFT protocol) and patients transplanted between September
2016–February 2017 (period 3, n = 61, new protocol).
Incidence of fDGF during the different periods are shown in Figure 2. Implementation of GDFT
was accompanied by an increase in fDGF from 8.3% in period 1 to 23% in period 2. The implementation
of the new protocol in period 3 resulted in a reduction of the incidence of fDGF back to baseline (8.2%,
p = 0.029).
Total amount of intraoperative administered fluid and mL/kg BW in recipients in the different time
periods are shown in Figure 3A,B, respectively. Total amount of fluid and mL/kg BW were significantly
different between the three time periods (p < 0.001, p < 0.001). Implementation of the GDFT (period 2)
resulted in a decrease of intraoperative fluid administration compared to our old protocol (period 1),
which was the case for total volume (2775 mL (2313–3500) vs. 3625 mL (3213–4000), p < 0.001) and
mL/kg BW (38 mL/kg BW (30.3–45.3) vs. 48 mL/kg BW (40–60), p < 0.001). The implementation of
the new protocol (period 3) resulted in an increase in intraoperative fluid administration to 4150 mL
(3475–4575) mL and 54 mL/kg BW (47.4–60.1) compared to the old (total volume p = 0.037, mL/kg BW
p = 0.053) and GDFT (total volume p < 0.001, mL/kg BW p < 0.001).
Figure 2. Incidence of fDGF in recipients during the different time periods. Period 1: January
2014–February 2015, old protocol, 4–5 L RL. Period 2: January–June 2016, GDFT protocol. Period 3:
September 2016–February 2017, new protocol, 50 mL/kg BW. p = 0.029.
J. Clin. Med. 2019, 8, 1587 10 of 14
Figure 3. Volume of fluid administered intraoperatively in recipients during the different time periods.
Period 1: January 2014–February 2015, old protocol, 4–5 L RL. Period 2: January–June 2016, GDFT
protocol. Period 3: September 2016–February 2017, new protocol, 50 mL/kg BW. Volumes are given in
mL (A) and mL/kg BW (B).
4. Discussion
This retrospective cohort analysis study shows that intraoperative fluid restriction in recipients
is associated with fDGF in living donor kidney transplantation. Additionally, we showed that the
implementation of a GDFT with a goal set at SVV < 10% led to a reduction of intraoperative fluid
administration, on average by 850 mL in total and 21% in mL/kg BW, compared to our old protocol of
4–5 L of RL. In our opinion, this analysis provides valuable information for other centers when changes
in intraoperative fluid management during kidney transplantation are considered.
Four to five liters of RL was the standard intraoperative fluid protocol in kidney transplantation
in our center for over 15 years. This may seem rather liberal, but problems due to hypervolemia
were rarely seen. However, following new trends on GDFT [24], a personalized intraoperative fluid
approach seemed more appropriate in this group of patients presenting with a variety of fluid states
at the time of surgery. Therefore, when in 2015 an intraoperative GDFT protocol was introduced
in our center for several surgical procedures, we included the kidney transplant program in this
implementation. Since there is no evidence in current literature on what goal to aim for, we adjusted the
standard institutional GDFT protocol of SVV < 12%, commonly used in abdominal surgery, to a more
generous goal in fluid administration of SVV < 10%. The implementation of this protocol resulted
in a reduction in the amount of fluid administered intraoperatively in contrast to previous studies
comparing GDFT to a “standard” protocol, which generally reported an increase of the amount of
fluid. This could be due to the fact that most of these studies compare GDFT with a rather restrictive
fluid protocol, which was general practice before GDFT was introduced. Kidney transplantation,
however, has always been an exception on this restrictive trend and most centers use a rather liberal
fluid protocol during this procedure. Another factor could be the performance of the FloTrac®-system
in predicting fluid responsiveness in this specific patient category. GDFT and the performance of
the FloTrac®-system has predominantly been validated in cardiac and abdominal surgery, liver
transplantation, and septic patients. Patients with end-stage renal disease (ESRD) and especially
patients on HD develop morphologic and functional cardiovascular changes. They often present with
severe arterio- and atherosclerosis, inducing arterial stiffening and systolic or diastolic dysfunction.
Since SVV is calculated as the percentage change of SV to the mean, derived from an arterial pulse
contour analysis, it is conceivable that these cardiovascular changes influence the performance of the
FloTrac®-system in predicting patients fluid state. Only one pilot study presents the effect of fluid
loading on SVV measured with the use of the FloTrac®-system in patients with ESRD on HD. In this
study, HD patients undergoing vascular surgery presented with a broad range of SVV (16.2 ± 6.0) after
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induction of anesthesia. After a fluid bolus of only 500 mL of a colloid solution almost all patients
showed a SVV < 10% (6.2 ± 2.8), the threshold in our protocol [25].
The debate on perioperative fluid management is still ongoing. Controversy exists regarding
assessment of the intravascular volume state, which goals to aim for, how to measure these goals,
and what type of fluid should be used. Hypovolemia leads to a decreased oxygen supply to organs and
tissues and may cause hypoxia, which can lead to organ dysfunction. Hypervolemia, on the other hand,
can damage the endothelial glycocalyx resulting in a fluid shift from the intravascular compartment to
the interstitial space and tissue edema [26]. Shin and colleagues report in their large cohort analysis of
92.094 patients undergoing noncardiac surgery that both too little and too much intraoperative fluid
is associated with increased morbidity, mortality, costs, and length of hospital stay [27]. Myles and
colleagues randomLy assigned 3000 patients undergoing a major abdominal procedure to a restrictive
or liberal fluid regimen. In their study, a restrictive regimen was associated with increased risk of
acute kidney injury with a hazard ratio of 1.71 (95% CI 1.29–2.27) [28]. These studies, however, do not
take kidney transplant recipients into account. In the normal kidney, blood flow is regulated by
an autoregulatory mechanism, ensuring adequate perfusion in a broad blood pressure range by afferent
and efferent arterioles. In the transplanted, denervated kidney, this haemodynamic autoregulation
is impaired making the renal blood flow linearly dependent on the systemic blood flow [29–31].
Furthermore, reperfusion of the ischemic kidney can be followed by vasoconstriction in the afferent
arterioles. This may result in a reduced GFR due to a decrease in glomerular transcapillary hydraulic
pressure difference [7,32,33]. Ensuring an adequate volume state in this specific patient category,
therefore, is essential to obtain an adequate circulation both on macro- and microcirculatory level.
Recently, Cavalari and colleagues reported the results of their prospective observational study, in which
they compared a prospectively observed cohort of 33 deceased donor kidney transplant recipients
treated with a GDFT protocol to a historical cohort of 33 kidney transplant recipients treated with their
conventional fluid therapy [34]. They observed a significant reduction of cardiovascular complications,
DGF. and surgical complications in the GDFT group. Surprisingly, in this study both groups received
the same amount of fluid throughout the transplant procedure. Studies including deceased donor
kidneys, however, comprise a variety of donor types with variable incidences of DGF hampering
an adequate analysis and conclusions.
The most important predictor of fDGF in our analysis was dialysis dependency at the time of
transplantation. A history of dialysis and especially hemodialysis prior to transplantation is a known
risk factor of DGF [5,7,35,36]. Hypovolemia at the time of transplantation is one of the proposed
underlying mechanisms [37]. Our hypothesis before implementation of the GDFT protocol was that
these hypovolemic dialysis patients would present with higher SVV at time of surgery, demanding more
fluid intraoperatively, compared to the relatively normovolemic or slightly hypervolemic preemptively
transplanted patients. Surprisingly, comparable amounts of fluids were given to the two groups.
In our GDFT protocol, noradrenaline was used when CI was below an age-adjusted value.
Therefore, an increased use of noradrenaline was seen in period 2 compared to period 1 (71% vs. 41%
p = 0.001) due to the implementation of the GDFT. In period 3, the use of noradrenaline decreased to 50%
of the patients. In the univariate analysis, the use of noradrenaline was correlated with development
of fDGF, but after multivariate logistic regression this was no longer the case. However, Morita and
coworkers showed that in a rat model, transplanted kidneys responded to sympaticomimetics with
a reduction in renal blood flow (RBF) in contrast to the increase in RBF seen in native rat kidneys [38].
There are some limitations of this analysis that have to be addressed: A major limitation is
that we were unable to evaluate outcome directly according to the fluid protocol (4–5L RL vs.
GDFT) and are unable to present information or draw any conclusions regarding actual SV, SVV,
CO or CI values and their relation to the observed increase of fDGF. Other limitations are those of
a retrospective observational trial. There is the potential of confounding by unmeasured factors.
Regarding postoperative fluid volume, the exact amount of fluid given could not be retrieved in
a reliable way from our PDMS and is therefore not implemented in this analysis. Postoperative fluid
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management was according to a standardized protocol and comprised of 1 L NaCl 0.45%-Glucose
2.5% per 24 h, complemented with the volume of diuresis in the former hour. This means that when
the kidney produces less urine the patient will be given less fluid postoperatively. Since fDGF was
associated with a lower urinary output the first two hours, it is very likely that patients experiencing
fDGF received less fluid postoperatively. Whether this contributed to development of fDGF or is more
of a symptom remains unknown. Backpressure from congested tubules obstructed with cellular debris
may contribute to a reduction in GFR [39,40]. A higher volume of urine in the first hours may have led
to washout of this debris.
Finally, due to the fact that there are only 31 events there is always the possibility of overestimating
the strength of associations using a multivariate analysis. A strong argument, however, is that no
policy changes were implemented during the study period with the exception of the intraoperative
fluid regimen. Furthermore the incidence of fDGF in our LDKT population has been stable over many
years and after changing the fluid regimen back to a more liberal fixed amount of 50 mL/kg BW the
incidence of fDGF instantly returned to baseline.
DGF after transplantation is a clinically relevant problem. It is associated with an increase in
morbidity, patient anxiety, increased risk of acute rejection, and additional diagnostic procedures and
costs. In our population the median hospital stay in patients experiencing fDGF was prolonged by
five days. Furthermore, this study shows that strict protocols for perioperative fluid management are
needed when studies in kidney transplantation are designed. Fluid restriction can be an important risk
factor for DGF, a frequently used primary end point, even in the setting of LDKT.
5. Conclusions
Implementation of a goal-directed approach to fluid administration with a goal set at a SVV < 10%
throughout the procedure led to reduced intraoperative fluid administration in the LDKT recipients in
our center. This intraoperative fluid restriction was associated with the development of more fDGF.
A thorough validation of GDFT protocols in patients with renal insufficiency is warranted before these
are implemented in this population.
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